Global Epigenomics Market, By Product (Reagents & Kits, Instruments, Services), By Field of Application (Diagnosis, R&D, Pharmaceuticals), By Disease (Cancer, Neurological Disorders, Inflammatory & Autoimmune Disease, CVD and Others ),By Technology (DNA Methylation, Histone Methylation & Acetylation, MicroRNA Modification, Large Non Coding RNA, Chromatin Structures and Others), By Enduser(CRO, Academics, Research lab), By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis, And Forecast Till 2030

The Global Epigenomics Market estimated growth for period 2018-2029 is approx. 13.5% CAGR. Study of complete set of epigenetic modifications on genetic material of a cell is known as Epigenomics. This field is analogous to Genomics and Proteomics which are basically study of example of an epigenetic change is DNA methylation — the addition of a methyl group, or a "chemical cap," to part of the DNA molecule, which prevents certain genes from being expressed.  Researchers are trying to chart the locations and understand the functions of all the chemical tags that mark the genome so that doctors can effortlessly find the disease and tailor the patient’s disease. Epigenetic modifications are modifications which are reversible on the cell's DNA or histones that affect gene expression without altering the DNA sequence. Gene function and altered patterns of gene expression are key features of cancer, which is the most common disease which has emerged one of the major application area for epigenomics.   This initiated, introduction of new drugs based on epigenomic technique. One of the important reason is completion of Human genome project and development of personalized medicine have geared up the market of epigenomics.

COVID-19 Impact on the Market:

Epigenetics alteration might play a crucial role in the onset of coronavirus disease complications. Although  therapeutics approaches are under study, more research is needed to identify effective vaccine or safer chemotherapeutic drugs, including epigenetic drugs, to cope with this viral outbreak and to develop pre- and post-exposure prophylaxis against COVID-19. Thus this market is expected to increase rapidly due to COVID-19.

Increasing Ageing Population with their Unhealthy Lifestyles drives Global Epigenomics market 

Cancer and other chronic diseases have common risk factors such as ageing and unhealthy lifestyles (For instances, Smoking, Unhealthy diet, Obesity and others). According to Center for Disease Control and Prevention, the number of adults who have ever been diagnosed with cancer are 23.3 million, which supports the growth of Epigenomic market. Epigenomic diagnosis is the prominent segment of Global Epigenomics market. Factors like growing population and diseases, pressurize researchers along with government for developing efficient healthcare system for all categories of the society which are likely to fuel the demand for epigenetic diagnosis over the forecasted period. DNA methylation is most extensively used technique in the field of epigenomics and more in demand because of its applications which include broad range of samples (Humans, Animals and Rodents samples).

Lack of skilled technicians and reimbursement provision

The Global Epigenomics Market face lot of challenges as one of is inefficiency in identification and validation of biomarkers. Presence of complex framework and lack of reimbursement provision in insurance for Epigenomics market. Lack of skilled technicians can also hamper the Global Epigenomics market.

By Product , the global Epigenomic market is segmented into Reagents & Kits, Instruments, and Services.

Depending upon its application Global epigenomic market is segmented into Oncology and Non-oncology. Based on the field of Application the market is segmented into Diagnosis, R&D, Therapy optimization, Prognosis. By Disease the market is segmented into Cancer, Neurological disorders, CVD, Inflammatory Autoimmune Disease and others. By Technology the market is segmented into DNA methylation, Histone methylation & Acetylation, MicroRNA modification Large Non Coding RNA, Chromatin Structures, Others. Another segment is End-user which includes CRO, Academics and Research labs.

Regional insights:                                                                

Regionally, the overall industry is divided into North America, Europe, Asia Pacific, Latin America, And Middle East & Africa. North America dominates the market in terms of revenue. The dominant share is attributed to North America owing to high investments in biotechnology, increased adoption in cancer research, and the development of new biologics, vaccines, & drugs. Moreover, an increasing number of R&D investments by companies is one of the driving factors for growth.

The presence of major market players undertaking extensive expansion strategies is also expected to enhance the market. Moreover, the increasing load of chronic diseases in this region is anticipated to increase the usage of advanced technologies by researchers and healthcare professionals. This is further anticipated to widen the scope for growth.

The Asia-Pacific epigenomic market is anticipated to grow rapidly, due to the high incidence of cancer, large prevalence of target diseases, the rise in healthcare expenditure, the rise in investments and funds, and various emerging applications.

Various factors such as rising healthcare spending and increasing awareness about the benefits of these products are expected to contribute to growth.

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2020 to 2030.  For the purpose of this study, has segmented the Global Epigenomics Market report based on the product, field of application, disease, technology, therapies, end-users and region.

Global Epigenomic Market, By Product:

• Reagents & kits
• Instruments
• Services

Global Epigenomics Market, By Field of application:

• Diagnosis
•  R&D
• Pharmaceuticals

Global Epigenomics Market, By Disease:

• Cancer
• Neurological Disorders
• Inflammatory & autoimmune disease
• CVD
• Others

Global Epigenomics Market, By Technology:

• DNA methylation
• Histone methylation & Acetylation
• MicroRNA modification
• Biomarkers
•  Non-coding RNA’s
•  MiRNA’s
• Chromatin

Global Epigenomics Market, By End-user:

• CRO
• Academics
• Research labs

Global Epigenomics Market, By Region:

• • • North America
      • • U.S.
        • Canada
    • Europe
      • • Germany
        • UK
        • France
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • • China
        • India
        • Japan
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
      • • GCC
        • Israel
        • South Africa
        • Rest of Middle East & Africa

The key players operating in the Global Epigenomics Market Abbott Laboratories, Affymetrix, Agilent Technologies, Astellas Pharmaceuticals, Bayer Ag, Abcam, Accent Therapeutics, Active Motif, Base genomics, Bluebird bio, 4SC and Others.

• Key players are involved in the innovation, for instance, Accent Therapeutics are developing drugs that target RNA-modifying proteins for new cancer therapies whereas Active motifs are developing epigenetics research product.
• Further, most of the key players are using organic and inorganic strategies for growth.
  • For instance, Roche completed the acquisition of Flatiron Health on 06 April 2018. Also Rubicon Genomics merged with Takara Bio Group on 19 January 2017. This merges increases the accessibility of the company’s products and services on the global market and facilitate new innovative solutions for customers.

Summary of key players

• Agilent technologies, Inc. launched real time PCR in Europe for diagnostics in July,2017.
• Illumina Inc., collaborated with Koninklijke Philips N.V. for analysis of genetic variation and developing integrated genomics solution for cancer in January, 2017. 

• Abbott Laboratories* 
  • Company Profile
  • Product Portfolio
  • Key Highlights
  • Financial Overview
  • Business Strategies
• Affymetrix
• Agilent Technologies
• Astellas Pharmaceuticals
• Bayer Ag
• Abcam
• Accent Therapeutic
• Active Motif
• Base genomics
• Bluebird bio
• 4SC     

“*” marked represents similar segmentation in other categories in the respective section